Investor Announcements - 2016

Pages:

TR-1 notification of major interest in shares

9^th Jun 2016

Result of placing

2^nd Jun 2016

EKF Diagnostics Holdings plc announces the successful completion of the Placing announced this morning.

Proposed placing

2^nd Jun 2016

EKF Diagnostics Holdings plc announces the proposed placing of up to 42,205,707 new ordinary shares of 1 penny each in the Company by way of an accelerated book build (the “Placing”).

AGM Statement

2^nd Jun 2016

Christopher Mills, EKF’s Non-Executive Chairman, will make a statement at the Company’s Annual General Meeting to be held at 11.00am today.

TR-1 notification of major interest in shares

25^th May 2016

Posting of Annual Report & Notice of AGM

2^nd May 2016

Archive

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

Medica 2019

Medica is the world’s largest medical trade fair. For more than 40 years it has been firmly established on every professional's calendar attracting over 40,000 delegates and over 5,000 exhibitors from 70 countries in 17 halls.

EKF to highlight Lucica® Glycated Albumin-L assay for diabetes patient monitoring at AACC 2019

EKF announces the availability of a liquid, enzymatic test for glycated albumin (GA) that was recently FDA cleared for sales in the U.S. GA, used for intermediate term monitoring of glycemic control in diabetes patients, will be showcased at the 2019 AACC.

EKF at InterLab - Algiers, Algeria 2019

The third edition of the exhibition will be held on 25-27 September 2019 at the Palais des Expositions, SAFEX, Algiers, Algeria.

EKF Quo-Test supports improved medical management of diabetic retinopathy patients